<?xml version='1.0' encoding='utf-8'?>
<document id="23861647"><sentence text="A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsy."><entity charOffset="12-35" id="DDI-PubMed.23861647.s1.e0" text="eslicarbazepine acetate" /></sentence><sentence text="Eslicarbazepine acetate (ESL) is a novel antiepileptic drug indicated for the treatment of partial-onset seizures"><entity charOffset="0-23" id="DDI-PubMed.23861647.s2.e0" text="Eslicarbazepine acetate" /><entity charOffset="25-28" id="DDI-PubMed.23861647.s2.e1" text="ESL" /><pair ddi="false" e1="DDI-PubMed.23861647.s2.e0" e2="DDI-PubMed.23861647.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23861647.s2.e0" e2="DDI-PubMed.23861647.s2.e1" /></sentence><sentence text=" Structurally, it belongs to the dibenzazepine family and is closely related to carbamazepine and oxcarbazepine"><entity charOffset="33-46" id="DDI-PubMed.23861647.s3.e0" text="dibenzazepine" /><entity charOffset="80-93" id="DDI-PubMed.23861647.s3.e1" text="carbamazepine" /><entity charOffset="98-111" id="DDI-PubMed.23861647.s3.e2" text="oxcarbazepine" /><pair ddi="false" e1="DDI-PubMed.23861647.s3.e0" e2="DDI-PubMed.23861647.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23861647.s3.e0" e2="DDI-PubMed.23861647.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23861647.s3.e0" e2="DDI-PubMed.23861647.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23861647.s3.e1" e2="DDI-PubMed.23861647.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23861647.s3.e1" e2="DDI-PubMed.23861647.s3.e2" /></sentence><sentence text=" Its main mechanism of action is by blocking the voltage-gated sodium channel"><entity charOffset="63-69" id="DDI-PubMed.23861647.s4.e0" text="sodium" /></sentence><sentence text=" ESL is a pro-drug that is rapidly metabolized almost exclusively into S-licarbazepine, the biologically active drug"><entity charOffset="71-86" id="DDI-PubMed.23861647.s5.e0" text="S-licarbazepine" /><entity charOffset="1-15" id="DDI-PubMed.23861647.s5.e1" text="ESL" /><pair ddi="false" e1="DDI-PubMed.23861647.s5.e1" e2="DDI-PubMed.23861647.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23861647.s5.e1" e2="DDI-PubMed.23861647.s5.e0" /></sentence><sentence text=" It has a favorable pharmacokinetic and drug-drug interaction profile" /><sentence text=" However, it may induce the metabolism of oral contraceptives and should be used with caution in females of child-bearing age" /><sentence text=" In the pre-marketing placebo-controlled clinical trials ESL has proven effective as adjunctive therapy in adult patients with refractory of partial-onset seizures"><entity charOffset="57-59" id="DDI-PubMed.23861647.s8.e0" text="ESL" /></sentence><sentence text=" Best results were observed on a single daily dose between 800 and 1200 mg" /><sentence text=" In general, ESL was well tolerated, with most common dose-related side effects including dizziness, somnolence, headache, nausea and vomiting"><entity charOffset="13-15" id="DDI-PubMed.23861647.s10.e0" text="ESL" /></sentence><sentence text=" Hyponatremia has been observed (0" /><sentence text="6%-1" /><sentence text="3%), but the incidence appears to be lower than with the use of oxcarbazepine"><entity charOffset="64-77" id="DDI-PubMed.23861647.s13.e0" text="oxcarbazepine" /></sentence><sentence text=" There is very limited information on the use of ESL in children or as monotherapy"><entity charOffset="49-61" id="DDI-PubMed.23861647.s14.e0" text="ESL" /></sentence><sentence text=" " /></document>